Market Place
Sourcing Support
Boston Pharma to Present Positive Phase 2 Data on BOS-580 in MASH
15 Nov 2024 //
BUSINESSWIRE
Boston Pharma To Present Phase 2 Results At AASLD Liver Meeting®
16 Oct 2024 //
BUSINESSWIRE
Boston Pharmaceuticals Appoints Dr. Margaret Koziel as New Chief Medical Officer
06 Jun 2024 //
BUSINESSWIRE
Boston Pharma: FGF21 Analogue BOS-580 Lipid Effects In MASH At EASL
05 Jun 2024 //
BUSINESSWIRE
Boston Pharmaceuticals Board Chair: Dr. Zerhouni Former Nih Director
23 May 2024 //
BUSINESSWIRE
Boston Presents Data Demonstrating Low Immunogenicity With BOS-580
05 Jan 2024 //
BUSINESSWIRE
Boston Pharmaceuticals Appoints Juan Carlos Lopez-Talavera
19 Dec 2023 //
BUSINESSWIRE
Boston Pharmaceuticals Announces Positive Phase 2a Data Supporting BOS-580
10 Nov 2023 //
BUSINESSWIRE
Boston Pharmaceuticals To Present New Phase 2a Data From Investigational BOS-580
07 Nov 2023 //
BUSINESSWIRE
Ex-Novartis drug clears NASH test, fueling pursuit of Akero
21 Jun 2023 //
FIERCE BIOTECH
Boston Announces +ve Phase 2a Results from Monthly and Bi-weekly Dosing
21 Jun 2023 //
BUSINESSWIRE
Boston Pharmaceuticals Announces Acceptance of Data from BOS-580 NASH Program
18 May 2023 //
BUSINESSWIRE
Boston Pharma Appoints Dr. Sophie Kornowski as Chair of its Board of Directors
10 May 2022 //
BUSINESSWIRE
Boston initiates Phase IIa trial of drug candidate for NASH
04 Oct 2021 //
CLINICALTRIALSARENA
Boston Pharmaceuticals Doses First Patient in Phase 2a Trial of BOS-580 for NASH
04 Oct 2021 //
BUSINESSWIRE
Boston initiates Phase IIa trial of drug candidate for NASH
04 Oct 2021 //
CLINICALTRIALSARENA
Boston Pharmaceuticals Doses First Patient in Phase 2a Trial of BOS-580 for NASH
04 Oct 2021 //
BUSINESSWIRE
Boston Pharma Enters into Unique Multi-Year Out-License with GSK
18 Mar 2021 //
BUSINESSWIRE
Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis
01 Sep 2020 //
BUSINESSWIRE
Novartis hands off NASH drug to biotech collaborator, plans to build new unit
01 Sep 2020 //
ENDPTS
Boston Pharmaceuticals Licenses NASH Development Candidate from Novartis
31 Aug 2020 //
BUSINESSWIRE
Boston Pharmaceuticals nabs Novartis veteran as new CMO
03 Feb 2020 //
FIERCE BIOTECH
U.K. launch trial of Boston Pharma`s resistance busting combo for breast cancer
07 Oct 2019 //
FIERCE BIOTECH
Boston Pharmaceuticals bags 8 assets in with GlaxoSmithKline and Novartis
03 Oct 2018 //
FIERCE BIOTECH
Novartis forge deal with Boston Pharmaceuticals in effort against AMR
03 Oct 2018 //
PHARMA FILE
Gurnet Point-backed Boston Pharmaceuticals supercharges pipeline with twin deals
02 Oct 2018 //
ENDPTS
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals
29 Aug 2017 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.